EMG
INSY

Ellington Management Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Ellington Management Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-18,400
Closed -$287K – 532
2014
Q2 		$287K Buy
+18,400
New +$297K 0.13% 243
2013
Q4 		– Sell
-54,600
Closed -$637K – 884
2013
Q3 		$637K Buy
+54,600
New +$448K 0.12% 225

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BTP
Bloom Tree Partners New York $215M AUM 17.45% 1-Year Est. Return

Ellington Management Group's INSY Position: Q3 2014 in Review

Ellington Management Group sold out of Insys Therapeutics, Inc. (INSY) in Q3 2014, closing a stake of 18,400 shares — an estimated $287K sold.

Ellington Management Group first reported a position in INSY in Q3 2013 and held it in 2 quarters. The position peaked at $637K in Q3 2013. 111 funds tracked by Wall St. Rank hold INSY as of Q3 2014.

  • Ellington Management Group reported no remaining Insys Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Ellington Management Group sold 18,400 Insys Therapeutics, Inc. shares in Q3 2014, an estimated $287K.
  • Ellington Management Group first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 2 quarters.
  • Ellington Management Group's Insys Therapeutics, Inc. position peaked at $637K in Q3 2013.
  • 111 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2014.

Based on Ellington Management Group's 13F filing for Q3 2014, filed 14 Nov 2014.